# A Clinical Study to Evaluate the Efficacy and Safety of LIV-GAMMA SN Inj. in Primary Immune Thrombocytopenia (ITP)

> **NCT03164915** · PHASE3 · COMPLETED · sponsor: **SK Plasma Co., Ltd.** · enrollment: 37 (actual)

## Conditions studied

- Immune Thrombocytopenia

## Interventions

- **BIOLOGICAL:** LIV-GAMMA SN Inj.

## Key facts

- **NCT ID:** NCT03164915
- **Lead sponsor:** SK Plasma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10-24
- **Primary completion:** 2018-04-03
- **Final completion:** 2018-09-28
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2021-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03164915

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03164915, "A Clinical Study to Evaluate the Efficacy and Safety of LIV-GAMMA SN Inj. in Primary Immune Thrombocytopenia (ITP)". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03164915. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*